达拉非尼联合曲美替尼治疗东亚晚期BRAF V600突变皮肤黑色素瘤的IIa期研究
本研究为开放标签IIa期研究,纳入77例东亚(含61例中国大陆)不可切除或转移性BRAF V600突变皮肤黑色素瘤患者,接受达拉非尼150mg每日两次联合曲美替尼2mg每日一次治疗。主要终点客观缓解率(ORR)为61%(95%CI 49.2-72.0),中位缓解持续时间(DOR)11.3个月,中位无进展生存期(PFS)7.9个月,中位总生存期(OS)未达到。常见不良事件为发热(56%),≥III级不良事件发生率38%。结果支持该联合方案在东亚患者中的疗效与耐受性。
要点
- 东亚BRAF V600突变晚期皮肤黑色素瘤患者ORR达61%,完全缓解率5%。
- 中位DOR 11.3个月,中位PFS 7.9个月,中位OS未达到。
- ≥III级不良事件发生率38%,最常见为发热(8%)和贫血(6%)。
核心结论
- 达拉非尼联合曲美替尼在东亚晚期BRAF V600突变皮肤黑色素瘤患者中显示出疗效和可耐受的安全性。
研究设计与样本
- 开放标签、单臂IIa期研究(NCT02083354),纳入77例东亚患者(含61例中国大陆),允许既往治疗但排除BRAF/MEK抑制剂。
- 患者接受达拉非尼150mg每日两次联合曲美替尼2mg每日一次治疗。
- 主要终点为基于RECIST 1.1的客观缓解率(ORR),次要终点包括缓解持续时间(DOR)、无进展生存期(PFS)、总生存期(OS)、药代动力学和安全性。
主要发现
- 数据截止2018年2月23日,中位随访8.3个月,36例(47%)患者仍在治疗中。
- 中位年龄52岁,32%患者乳酸脱氢酶升高,84%接受过既往全身治疗。
- ORR为61%(95%CI 49.2-72.0),4例(5%)达到完全缓解。
- 中位DOR为11.3个月,中位PFS为7.9个月,中位OS未达到。
- 任何级别最常见不良事件为发热(56%),≥III级不良事件发生在29例(38%)患者,最常见为发热(8%)和贫血(6%),5例(6.5%)因不良事件永久停药。
关键数值与推荐
- ORR 61%(95%CI 49.2-72.0),完全缓解率5%。
- 中位DOR 11.3个月,中位PFS 7.9个月。
- 达拉非尼和曲美替尼的平均Cmax:第1天分别为3560和11.5 ng/mL,第15天分别为2680和27.1 ng/mL。
临床怎么用
- 对于东亚晚期BRAF V600突变皮肤黑色素瘤患者,达拉非尼联合曲美替尼可作为有效且耐受性良好的治疗选择。
- 治疗期间需监测发热和贫血等不良事件,多数≥III级不良事件可管理,永久停药率较低。
局限性
- 本研究为单臂IIa期研究,无对照组,样本量有限(77例),随访时间较短(中位8.3个月)。
- 中位OS未达到,长期生存获益需进一步随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study (NCT02083354) assessed the efficacy and safety of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma. METHOD: Overall, 77 patients of East Asian origin (including 61 from Mainland China) with unresectable or metastatic BRAF V600-mutant cutaneous melanoma were enrolled. Prior treatment was allowed except with BRAF/MEK inhibitors. Patients received dabrafenib 150 mg twice daily and trametinib 2 mg once daily. The primary end-point was objective response rate (ORR) using Response Evaluation Criteria in Solid Tumours 1.1. Secondary end-points were duration of response (DOR), progression-free survival (PFS), overall survival (OS), pharmacokinetics and safety. RESULTS: At data cutoff (February 23, 2018; median follow-up, 8.3 months), treatment was ongoing in 36 patients (47%). The median age was 52 years; 32% of patients had elevated lactate dehydrogenase, and 84% had received prior systemic therapy. ORR was 61% (95% confidence interval: 49.2-72.0), with four patients (5%) achieving complete response. Median DOR and PFS were 11.3 and 7.9 months, respectively. Median OS was not reached. The most common adverse event (AE) of any grade was pyrexia (56%). Grade ≥III AEs occurred in 29 patients (38%). The most common grade ≥III AEs were pyrexia (8%) and anaemia (6%). AEs led to permanent discontinuation in five patients (6.5%). Mean Cmax for dabrafenib and trametinib was 3560 and 11.5 ng/mL (day 1) and 2680 and 27.1 ng/mL (day 15), respectively. CONCLUSION: These results support the efficacy and tolerability of dabrafenib in combination with trametinib in East Asian patients with unresectable or metastatic BRAF V600-mutant cutaneous melanoma.
引用
- Si L, Zhang X, Shin SJ, et al. Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma. Eur J Cancer. 2020. PMID: 32534242. doi:10.1016/j.ejca.2020.04.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。